Pfizer Profits Dip As It Ramps R&D Spending For New Drugs

Pfizer has reported a decline in its profit margins as the pharmaceutical company significantly increases its investment in research and development. The financial shift reflects the firm's strategic focus on developing new drug treatments, leading to higher operational costs that have impacted its overall earnings performance for the period.